LRRK2 inhibitors and methods of making and using thereof

Inventors

de Vicente Fidalgo, Javier • Estrada, Anthony A. • Feng, Jianwen A. • Sweeney, Zachary K.

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12358896-B2

Patent

Publication Date

2025-07-15

Expiration Date


Abstract

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, isotopically enriched analog, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or pharmaceutical composition thereof, and methods of making and using thereof.

Core Innovation

The patent discloses heteroaryl-substituted pyrimidine LRRK2 inhibitors, including Formula I and Formulae IA–IC compounds, stereoisomers, and cis cyclopropyl pyrazole–pyrimidine carboxamides. Aminopyrazole intermediates and substituted pyrimidines are disclosed as components of compound preparation, with operational lab details omitted. The background section is not included, leaving the specific technical problem not explicitly described in patent.

Biological testing reports inhibition of LRRK2 G2019S and greater cellular activity for compounds 1–8 than for Comparative Example A. Compound 7 exhibits biochemical and cellular IC50 values of 1.47 and 1.83 nM, respectively, with an HLM clearance value of 3.6 mL/min/kg. Its MDR1 efflux ratio indicates poor predicted brain penetration, noted as advantageous for non-CNS indications.

Claims Coverage

The relevant claims identify nine independent claims directed to compounds. Claim 1 covers a compound selected from recited structures and specified forms, while claims 2–9 each cover a compound having a recited structure or a pharmaceutically acceptable salt thereof.

Selected compound and stereoisomeric forms

The first independent claim covers a compound selected from recited structures, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof, with structural depictions not visible in the supplied text.

Compound having a recited structure

Independent claims 2–9 each cover a compound having its recited structure, or a pharmaceutically acceptable salt thereof, with structural depictions not visible in the supplied text.

The nine independent claims cover structurally defined compounds or compound selections and specified pharmaceutically acceptable forms. Dependent claims add pharmaceutical compositions and treatment of LRRK2-mediated diseases or conditions, including specified cancer, inflammatory, and neurodegenerative conditions.

Stated Advantages

Compounds 1–8 show greater cellular activity than Comparative Example A in the reported testing.

Poor predicted brain penetration is stated as an advantage for non-CNS indications.

Documented Applications

Pharmaceutical compositions comprising a claimed compound or a listed form, together with a pharmaceutically acceptable carrier, diluent, or excipient.

Treatment of LRRK2-mediated diseases or conditions, including Parkinson's disease as a neurodegenerative disease application.

Treatment of cancer, including kidney, breast, prostate, blood, papillary, and lung cancers, acute myelogenous leukemia, and multiple myeloma.

Treatment of inflammatory disease, including leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, and ankylosing spondylitis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.